<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>15847742</identifier>
<setSpec>0300-8932</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Pujol, Emilio</dc:author>
<dc:author>Sánchez, Angel</dc:author>
<dc:author>Andreu, Juan</dc:author>
<dc:author>Martínez, Francisco J</dc:author>
<dc:author>Rodríguez-Gómez, Francisco J</dc:author>
<dc:author>Alvarez, Alejandra</dc:author>
<dc:description xml:lang="en">Large clinical trials have demonstrated the clinical effectiveness of therapy with inhibitors of the platelet surface-membrane glycoprotein IIb-IIIa receptor in a broad range of patients with ischemic heart disease. Abciximab, a platelet glycoprotein IIb-IIIa receptor blocker, is associated with improved long-term prognosis in patients who require angioplasty and stent placement. Severe bleeding from abciximab use is an uncommon event. We describe a patient with severe pulmonary hemorrhage after treatment with abciximab, and discuss predisposing factors and protamine infusion in this potentially fatal complication.</dc:description>
<dc:type>Case Reports</dc:type>
<dc:language>es</dc:language>
<dc:date>2005 Apr </dc:date>
<dc:title xml:lang="es">Hemorragia pulmonar por abciximab. Factores de riesgo y papel de la protamina.</dc:title>
<dc:title xml:lang="en">[Pulmonary hemorrhage after abciximab. Risk factors and the role of protamine].</dc:title>
<dc:publisher>Revista espanola de cardiologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
